Zahra Talebi

421 total citations
29 papers, 232 citations indexed

About

Zahra Talebi is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Zahra Talebi has authored 29 papers receiving a total of 232 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Hematology. Recurrent topics in Zahra Talebi's work include Drug Transport and Resistance Mechanisms (9 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Cancer therapeutics and mechanisms (4 papers). Zahra Talebi is often cited by papers focused on Drug Transport and Resistance Mechanisms (9 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Cancer therapeutics and mechanisms (4 papers). Zahra Talebi collaborates with scholars based in United States, Iran and Netherlands. Zahra Talebi's co-authors include Alex Sparreboom, Sharyn D. Baker, Eric D. Eisenmann, Shuiying Hu, Yang Li, Yan Jin, Arash Khojasteh, Javad Ranjbari, Muhammad Erfan Uddin and Alice A. Gibson and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Cancer Research and The FASEB Journal.

In The Last Decade

Zahra Talebi

23 papers receiving 225 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zahra Talebi United States 8 87 63 34 32 26 29 232
Aksana Vasilyeva United States 8 123 1.4× 135 2.1× 29 0.9× 22 0.7× 6 0.2× 13 302
Sonu Gupta India 9 89 1.0× 93 1.5× 56 1.6× 17 0.5× 12 0.5× 37 361
Guillaume Becker France 8 49 0.6× 68 1.1× 44 1.3× 17 0.5× 11 0.4× 19 227
Gonzalo Gomez-Abuin Argentina 6 182 2.1× 94 1.5× 21 0.6× 17 0.5× 25 1.0× 10 350
Maxime Annereau France 9 103 1.2× 70 1.1× 13 0.4× 32 1.0× 24 0.9× 39 321
Ricardo Bellott France 9 123 1.4× 160 2.5× 18 0.5× 27 0.8× 50 1.9× 13 329
Stefanie D. Krens Netherlands 9 117 1.3× 70 1.1× 31 0.9× 11 0.3× 8 0.3× 16 248
Raymond S. Lord United States 6 182 2.1× 184 2.9× 14 0.4× 24 0.8× 38 1.5× 7 337
Calogero Buscarino Italy 5 88 1.0× 33 0.5× 15 0.4× 24 0.8× 25 1.0× 7 194
Madhu B. Garg Australia 11 243 2.8× 130 2.1× 24 0.7× 11 0.3× 19 0.7× 17 394

Countries citing papers authored by Zahra Talebi

Since Specialization
Citations

This map shows the geographic impact of Zahra Talebi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zahra Talebi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zahra Talebi more than expected).

Fields of papers citing papers by Zahra Talebi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zahra Talebi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zahra Talebi. The network helps show where Zahra Talebi may publish in the future.

Co-authorship network of co-authors of Zahra Talebi

This figure shows the co-authorship network connecting the top 25 collaborators of Zahra Talebi. A scholar is included among the top collaborators of Zahra Talebi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zahra Talebi. Zahra Talebi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colevas, A. Dimitrios, Zahra Talebi, Victor Lee, et al.. (2025). First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr–Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies. Clinical Cancer Research. 31(5). 815–823. 4 indexed citations
2.
Huang, Kevin M., Peter de Bruijn, Mahesh R. Nepal, et al.. (2024). Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen. Cancer Research Communications. 4(9). 2489–2497. 2 indexed citations
3.
Talebi, Zahra, Yan Jin, Alice A. Gibson, et al.. (2024). Darolutamide does not interfere with OATP‐mediated uptake of docetaxel. International Journal of Cancer. 155(2). 314–323. 3 indexed citations
4.
Halbus, Ahmed F., et al.. (2024). High-performance photocatalytic degradation and antifungal activity of chromium-doped nickel oxide nanoparticles. Analytical Sciences. 40(4). 655–670. 1 indexed citations
5.
6.
Talebi, Zahra, Eric D. Eisenmann, Kalindi Parmar, et al.. (2023). Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method. Heliyon. 9(11). e20972–e20972.
7.
8.
Talebi, Zahra, Yan Jin, Sharyn D. Baker, Daniel Addison, & Alex Sparreboom. (2023). Determination and disposition of meta-iodobenzylguanidine in plasma and heart of transporter-deficient mice by UPLC-MS/MS. Journal of Chromatography B. 1222. 123699–123699. 1 indexed citations
9.
Nepal, Mahesh R., Yang Li, Zahra Talebi, et al.. (2022). Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity. Cancer Research Communications. 2(11). 1334–1343. 7 indexed citations
10.
Eisenmann, Eric D., Zahra Talebi, Yan Jin, et al.. (2022). Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination. Pharmaceutics. 14(4). 694–694. 12 indexed citations
11.
Jin, Yan, Zahra Talebi, Shuiying Hu, et al.. (2022). Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B. Molecules. 27(20). 6815–6815. 5 indexed citations
12.
Talebi, Zahra, Alex Sparreboom, & Susan I. Colace. (2022). Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods in molecular biology. 2547. 63–94. 2 indexed citations
13.
Hu, Shuiying, et al.. (2022). The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature. Expert Opinion on Drug Metabolism & Toxicology. 18(7-8). 459–468. 15 indexed citations
14.
Eisenmann, Eric D., Zahra Talebi, Alex Sparreboom, & Sharyn D. Baker. (2021). Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions. Basic & Clinical Pharmacology & Toxicology. 130(S1). 23–35. 34 indexed citations
15.
Uddin, Muhammad Erfan, Zahra Talebi, Yan Jin, et al.. (2021). In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors. Pharmaceutics. 13(12). 2004–2004. 12 indexed citations
16.
Talebi, Zahra, et al.. (2020). Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors. Pharmaceutics. 12(9). 856–856. 31 indexed citations
17.
18.
Talebi, Zahra & Ali Dabbagh. (2017). Perioperative Pain: Molecular Mechanisms and Future Perspectives. SHILAP Revista de lepidopterología.
19.
Talebi, Zahra, et al.. (2017). Cellular and Molecular Mechanisms in Perioperative Hepatic Protection: A Review of Current Interventions. SHILAP Revista de lepidopterología. 1 indexed citations
20.
Talebi, Zahra, et al.. (2015). Comparative Assessment of Effect of Education in the OREM`s Self Care Model Way with Current Method on the Quality of Life of Diabetic Type 2 Patients. 22(5). 748–757. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aksana Vasilyeva Breakdown of academic impact, for papers by Sonu Gupta Breakdown of academic impact, for papers by Guillaume Becker Breakdown of academic impact, for papers by Gonzalo Gomez-Abuin Breakdown of academic impact, for papers by Maxime Annereau Breakdown of academic impact, for papers by Ricardo Bellott Breakdown of academic impact, for papers by Stefanie D. Krens Breakdown of academic impact, for papers by Raymond S. Lord Breakdown of academic impact, for papers by Calogero Buscarino Breakdown of academic impact, for papers by Madhu B. Garg
Rankless by CCL
2026